“Neuroinflammation: The Common Thread in Neurodegenerative Disease Progression” will take place in Boston, Massachusetts
Jay Mohr, Chief Operating and Business Officer, will be providing a corporate update and participating on a late-stage CNS therapeutics panel.
Company will be providing a company overview and participating on a CNS panel
Anti-inflammatory drug cromolyn successfully delayed disease onset and was neuroprotective in a mouse model of ALS
Brings more than 20 years of experience in the life science industry to support pre-commercial and regulatory activities of Phase 3 candidate ALZT-OP1 for early Alzheimer’s disease
The presentation will highlight AZTherapies’ lead Phase 3 clinical candidate and pipeline of candidates.
Cutting-edge CAR-Treg technology could have broad application across common and rare neurodegenerative diseases; Smith Founder and CEO Philip Ashton-Rickardt, Ph.D. joins as SVP of Immunology
Proceeds to support ongoing Phase 3 Alzheimer’s clinical trial, expected to complete in 2020, and advancement of pipeline of candidates targeting neuroinflammation
Dr. Rudy Tanzi discusses AZTherapies’ approach with NBC News medical correspondent Dr. John Torres.
Investor, former biopharmaceutical executive, and philanthropist George Behrakis has joined the company’s Board of Directors.